Kiora Pharmaceuticals (KPRX) Projected to Post Quarterly Earnings on Friday

Kiora Pharmaceuticals (NASDAQ:KPRX) will likely be announcing its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.71) per share and revenue of $1.50 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Wednesday, March 25th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.90).

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ KPRX opened at $2.51 on Wednesday. The firm has a market capitalization of $11.12 million, a price-to-earnings ratio of -0.95 and a beta of -0.48. The stock has a 50 day moving average price of $2.19 and a 200 day moving average price of $2.17. Kiora Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $4.18.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of Kiora Pharmaceuticals

A number of large investors have recently modified their holdings of the company. DRW Securities LLC boosted its holdings in shares of Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares during the period. Alyeska Investment Group L.P. bought a new position in Kiora Pharmaceuticals in the fourth quarter worth approximately $152,000. Citadel Advisors LLC bought a new position in Kiora Pharmaceuticals in the third quarter worth approximately $125,000. Renaissance Technologies LLC raised its stake in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Kiora Pharmaceuticals in the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.